News >

Juno Files for IPO as CAR Therapies Continue to Advance

Andrew J. Roth
Published: Wednesday, Nov 19, 2014

Cancer Cell As its chimeric antigen receptor (CAR) T cell and high-affinity T cell receptor (TCR) products continue to advance in clinical trials, Juno Therapeutics, Inc, filed a registration statement for an initial public offering (IPO) of its common stock on November 17.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication